Stonepine Capital Management »

Moonlake Immunot shares owned by Stonepine Capital Management

Quarter-by-quarter ownership of Moonlake Immunot (MLTX) shares owned by Stonepine Capital Management from 13F filings

Historical chart of Stonepine Capital Management investment in Moonlake Immunot

Tip: Access up to 7 years of quarterly data

All positions including Moonlake Immunot held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Moonlake Immunot by Stonepine Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $974k 50k 19.47

More positions owned by Stonepine Capital Management

Evolus (EOLS)
Verastem Com New (VSTM)
Adma Biologics (ADMA)
Tenax Therapeutics Com New (TENX)
Nektar Therapeutics Com New (NKTR)
Ultragenyx Pharmaceutical (RARE)
Camp4 Therapeutics Corp Com 13469v Ab 4 Camtek Ltd Note 12/0 (CAMP)
Insmed Com Par $.01 Call Option (INSM)
Eloxx Pharmaceuticals Com New
Kazia Therapeutics Sponsored Ads (KZIA)
Medtronic SHS Call Option (MDT)
Indivior Pharmaceuticals (INDV)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Abbott Laboratories Call Option (ABT)
Satellos Bioscience (MSLE)

View all positions for Stonepine Capital Management

Top funds holding Moonlake Immunot

BVF
Deep Track Capital
Henderson Group
D. E. Shaw & Co
Cormorant Asset Management
Jupiter Topco
Logos Global Management
Weiss Asset Management LP[1
Citadel Advisors
Two Sigma Investments
MPM Oncology Impact Management
Vivo Capital
Jpmorgan Chase & Co
T. Rowe Price Associates
Jane Street

View all funds holding Moonlake Immunot